Table 1_Induction immunochemotherapy followed by concurrent chemoradiotherapy improves sur

A systematic review and meta-analysis document evaluating the benefits of adding immunotherapy to standard chemoradiotherapy for unresectable esophageal cancer. The document includes results from 69 trials involving 9,648 participants, analyzing overall survival, progression-free survival, objective response rate, and safety. The document was authored by Xuefei Fan and last updated in May 2026.

Use Cases

• Compare the efficacy of induction immunochemotherapy versus consolidation immunotherapy based on hazard ratios for overall survival.
• Assess progression-free survival benefits of different combined treatment strategies based on network meta-analysis results.
• Evaluate the safety profile of immunotherapy combined with chemoradiotherapy based on the included trial data.
• Inform clinical trial design for unresectable esophageal cancer based on the identified evidence gaps.

Strengths

• The analysis is based on a substantial evidence base of 69 trials and 9,648 participants.
• Results include hazard ratios with 95% confidence intervals for multiple outcomes, providing quantitative effect estimates.
• The document is registered with PROSPERO (CRD420261364669), indicating a structured review process.

Limitations

• The dataset is a 21.0 KB DOCX document, which is a small text file containing analysis results, not the underlying patient-level data.
• Row count and column-level documentation are absent; the document's findings must be interpreted as-is.
• The description notes a lack of sufficient randomized controlled trials to validate efficacy and determine optimal treatment timing.

Provenance

Source

figshare

Collection Method

Systematic review, pairwise meta-analysis, and network meta-analysis of published clinical trials.

Freshness

Last updated 2026-05-12 05:43:00